RxPONDER and Ovarian Suppression Implications

Featuring perspectives from Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda, including the following topics:

• Introduction (0:00)
• Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease — Dr Goetz (4:48)
• Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Nanda (29:45)
• Management of HER2-Positive Breast Cancer — Dr Burstein (1:04:43)
• Antibody-Drug Conjugate Treatment Approaches for Triple-Negative Breast Cancer — Dr McArthur (1:29:53)

CE information and select publications